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anglais
Monoclonal antibody (mAb)-based therapies have experienced considerable growth in
cancer management. When labeled with radionuclides, mAbs also represent promising
probes for imaging or theranostic approaches. Initially, mAbs have been radiolabeled
with single-photon emitters, such as I, Tc, or In, for diagnostic purposes or to improve
radioimmunotherapy (RIT) using dosimetry estimations. Today, more accurate
imaging is achieved using positron- emission tomography (PET). Thanks to the
important technical advances in the production of PET emitters and their related
radiolabeling methods, the last decade has witnessed the development of a broad
range of new probes for specific PET imaging. Immuno-PET, which combines the high
sensitivity and resolution of a PET camera with the specificity of a monoclonal
antibody, is fully in line with this approach. As RIT, immuno-PET can be performed
using directly radiolabeled mAbs or using pretargeting to improve imaging contrast.
Pretargeted immuno-PET has been developed against different antigens, and
promising results have been reported in tumor expressing carcinoembryonic antigen
(CEA; CEACAM5) using a bispecific mAb (BsmAb) and a radiolabeled peptide.
Medullary thyroid carcinoma (MTC) is an uncommon thyroid cancer subtype which
accounts for <10% of all thyroid neoplasms. Characterized by an intense expression of
CEA, MTC represents a relevant tumor model for immuno-PET. High sensitivity of
pretargeted immunoscintigraphy using murine or chimeric anti-CEA BsMAb and
pretargeted haptens-peptides labeled with In or I were reported in metastatic MTC
patients 20 years ago. Recently, an innovative clinical study reported high tumor
uptake and contrast using pretargeted anti-CEA immuno-PET in relapsed MTC
patients. This review focuses on MTC as an example, but the same pretargeting
technique has been applied with success for clinical PET imaging of other CEA-
expressing tumors and other pretargeting systems. In particular, those exploiting
bioorthogonal chemistry also appear interesting in preclinical animal models,
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